Moderna-Merck Melanoma Therapy Shows Promising Results in Late-Stage Trial

Moderna's personalized mRNA cancer therapy, developed in partnership with Merck, has shown promising results in a late-stage trial for melanoma treatment. The therapy, used in combination with Merck's blockbuster treatment Keytruda, reduced the risk of melanoma recurrence and spread compared to using Keytruda alone.

The interim results of the trial were statistically significant, sending Moderna's shares soaring nearly 90%. Merck's stock also gained 10% following the announcement. The success of the therapy has been hailed by experts as a major breakthrough in the field of mRNA-based cancer treatments.

Analysts and investors are now eagerly awaiting the full release of trial data, which will provide further insight into the efficacy and potential commercial value of the therapy. Some experts have expressed caution, however, noting that manufacturing personalized vaccines at scale could be complex and expensive.